Valbiotis SA (FR:ALVAL)
:ALVAL
Want to see FR:ALVAL full AI Analyst Report?
ALVAL Stock Chart & Stats
€0.72
€0.05(3.27%)
At close: 4:00 PM EST
€0.72
€0.05(3.27%)
Day’s Range― - ―
52-Week Range€0.54 - €1.30
Previous CloseN/A
Volume46.53K
Average Volume (3M)112.19K
Market Cap
€24.87M
Enterprise Value€20.64M
Total Cash (Recent Filing)€8.68M
Total Debt (Recent Filing)€5.09M
Price to Earnings (P/E)―
Beta0.66
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.49
Shares Outstanding23,698,235
10 Day Avg. Volume162,174
30 Day Avg. Volume112,190
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)2.36
Price to Sales (P/S)18.17
P/FCF Ratio-2.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.36
Revenue Forecast (FY)€4.53M
Bulls Say, Bears Say
Bulls Say
Commercialization & Partnership ModelValbiotis operates a product-led consumer health model with explicit commercialization and partnership paths (sales, licensing, royalties, contract manufacturing). This multi-channel monetization reduces binary R&D risk and supports recurring revenue potential as product adoption scales over months to years.
Manageable Leverage On Balance SheetReported mid-range debt-to-equity (~0.73 in 2025) indicates leverage is not extreme versus high-debt peers. That relative balance-sheet headroom supports the company's ability to access additional financing if needed and reduces immediate solvency stress, improving structural flexibility over the next several quarters.
Revenue Rebound / Growth SignalA pronounced revenue rebound in 2025 and reported strong revenue-growth metric signal commercial traction after prior volatility. For a nutraceutical company, renewed top-line growth suggests product uptake or distribution expansion, which can underpin improved margin absorption if sustained across future reporting periods.
Bears Say
Persistent UnprofitabilityThe company reports continuous operating and net losses and deeply negative margins across the sample period. Persistent unprofitability undermines internal capital generation, necessitates external funding, and raises execution risk that losses will dilute equity and hinder reinvestment capacity over the medium term.
Sustained Negative Cash FlowConsistent negative operating and free cash flow (FCF ≈ -€8.2M in 2025) means the business is not self-funding and depends on external capital. Ongoing cash burn increases dilution and constrains strategic optionality, elevating refinancing risk and limiting the firm's ability to invest in commercial scale-up without new capital.
Declining Equity And Asset BaseA downward trend in equity and total assets weakens balance-sheet resilience, reducing cushions for adverse events and increasing the probability that the company will need dilutive capital raises. This structural shrinkage impairs long-term financial flexibility and heightens investor dilution risk if losses persist.
Valbiotis SA News
ALVAL FAQ
What was Valbiotis SA’s price range in the past 12 months?
Valbiotis SA lowest stock price was €0.54 and its highest was €1.30 in the past 12 months.
What is Valbiotis SA’s market cap?
Valbiotis SA’s market cap is €24.87M.
When is Valbiotis SA’s upcoming earnings report date?
Valbiotis SA’s upcoming earnings report date is Sep 24, 2026 which is in 125 days.
How were Valbiotis SA’s earnings last quarter?
Valbiotis SA released its earnings results on Mar 02, 2026. The company reported -€0.204 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.204.
Is Valbiotis SA overvalued?
According to Wall Street analysts Valbiotis SA’s price is currently Overvalued.
Does Valbiotis SA pay dividends?
Valbiotis SA does not currently pay dividends.
What is Valbiotis SA’s EPS estimate?
Valbiotis SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Valbiotis SA have?
Valbiotis SA has 23,698,235 shares outstanding.
What happened to Valbiotis SA’s price movement after its last earnings report?
Valbiotis SA reported an EPS of -€0.204 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.971%.
Which hedge fund is a major shareholder of Valbiotis SA?
Currently, no hedge funds are holding shares in FR:ALVAL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Valbiotis SA
Valbiotis SA engages in the research and development of health nutrition products to prevent and combat metabolic and cardiovascular diseases. The company develops TOTUM-63 that is in Phase II/III clinical trials for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II clinical trials to treat hypercholesterolemia; and TOTUM-854 that is in Phase II/III clinical trials for arterial hypertension. It also develops TOTUM-448 for the treatment of patient with non-alcoholic fatty liver disease. It has a strategic partnership with Nestlé Health Science. Valbiotis SA was incorporated in 2014 and is headquartered in Périgny, France.